Focused on the development of topical patidegib, a first-in-class topical hedgehog inhibitor, to decrease the number of surgically-eligible basal cell carcinomas (BCCs) in persons with Gorlin Syndrome and those with sporadic BCCs

Photo by andresrimaging/iStock / Getty Images
Photo by monkeybusinessimages/iStock / Getty Images
Photo by monkeybusinessimages/iStock / Getty Images